GH Research (GHRS) Expected to Announce Earnings on Thursday

Key Points

• GH Research is set to report Q1 2026 results before market open on Thursday, May 7 (earnings call 12:30 PM ET), and analysts expect a loss of ($0.27) per share.
• The company beat the last quarter's estimate (reported ($0.23) vs. est. ($0.29)), yet analysts project about -$2 EPS for the current and next fiscal years; the stock opened at $19.16, is down ~3.5%, with a 1‑year range of $8.75–$24.66 and a $1.19 billion market cap.
• Wall Street sentiment is largely positive—the consensus rating is "Moderate Buy" with an average price target of $40.13 (9 Buys, 1 Hold, 1 Sell)—and institutional investors own 56.9% of the shares, with recent buying from Barclays, BNP Paribas and others.

GH Research (NASDAQ:GHRS - Get Free Report) is expected to be posting its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect GH Research to post earnings of ($0.27) per share for the quarter. Individuals are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 12:30 PM ET.

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Friday, March 6th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.06. On average, analysts expect GH Research to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

GH Research Trading Down 3.5%

GHRS stock opened at $19.16 on Thursday. GH Research has a 1-year low of $8.75 and a 1-year high of $24.66. The firm has a market cap of $1.19 billion, a P/E ratio of -23.95 and a beta of 1.00. The business's 50 day moving average is $15.95 and its 200-day moving average is $14.97.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Barclays PLC lifted its holdings in GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company's stock worth $27,000 after buying an additional 822 shares in the last quarter. Osaic Holdings Inc. lifted its holdings in GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company's stock worth $75,000 after buying an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in GH Research during the 2nd quarter worth $79,000. HRT Financial LP acquired a new position in GH Research during the 4th quarter worth $202,000. Finally, BNP Paribas Financial Markets lifted its holdings in GH Research by 165.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company's stock worth $207,000 after buying an additional 10,600 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. TD Cowen reiterated a "buy" rating on shares of GH Research in a research note on Monday, January 5th. Weiss Ratings restated a "sell (d-)" rating on shares of GH Research in a research report on Tuesday, April 21st. Guggenheim set a $34.00 price target on GH Research and gave the stock a "buy" rating in a research report on Tuesday, March 10th. Needham & Company LLC increased their price target on GH Research from $31.00 to $32.00 and gave the stock a "buy" rating in a research report on Friday, March 6th. Finally, Royal Bank Of Canada increased their price target on GH Research from $33.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $40.13.

About GH Research

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm's lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.